Tags

Type your tag names separated by a space and hit enter

Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis with the MiraVista IgG and IgM Detection Enzyme Immunoassay.
J Clin Microbiol. 2017 03; 55(3):893-901.JC

Abstract

Coccidioidomycosis is a common cause of community-acquired pneumonia in areas of the southwestern United States in which the disease is endemic. Clinical presentations range from self-limited disease to severe disseminated disease. Therefore, early and accurate diagnosis is essential to ensure appropriate treatment and monitoring. Currently available diagnostic tests have variable accuracy, particularly in certain patient populations, and new tests may offer improved accuracy for the diagnosis of coccidioidomycosis. Serum samples from 103 cases of coccidioidomycosis and 373 controls were tested for IgG and IgM antibodies using the MVista anti-Coccidioides antibody enzyme immunoassay. Serum specimens from 170 controls from areas in which the disease is endemic and 44 cases were tested by immunodiffusion at MiraVista Diagnostics. The sensitivity of the MVista antibody assay was 88.3%, and the specificity was 90%. The sensitivity was maintained in the presence of immunocompromising conditions or immunosuppressive therapies. The sensitivity of immunodiffusion was 60.2%, and the specificity was 98.8%. The sensitivity of complement fixation (62 cases) was 66.1%, but the specificity could not be determined. The MVista anti-Coccidioides antibody enzyme immunoassay offers improved sensitivity, compared with immunodiffusion and complement fixation, is not impaired in immunocompromised patients, and permits highly reproducible semiquantification.

Authors+Show Affiliations

Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA jmalo@deptofmed.arizona.edu.MiraVista Diagnostics, Indianapolis, Indiana, USA.Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.MiraVista Diagnostics, Indianapolis, Indiana, USA.Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, USA.Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.MiraVista Diagnostics, Indianapolis, Indiana, USA.Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

28053216

Citation

Malo, Joshua, et al. "Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis With the MiraVista IgG and IgM Detection Enzyme Immunoassay." Journal of Clinical Microbiology, vol. 55, no. 3, 2017, pp. 893-901.
Malo J, Holbrook E, Zangeneh T, et al. Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis with the MiraVista IgG and IgM Detection Enzyme Immunoassay. J Clin Microbiol. 2017;55(3):893-901.
Malo, J., Holbrook, E., Zangeneh, T., Strawter, C., Oren, E., Robey, I., Erickson, H., Chahal, R., Durkin, M., Thompson, C., Hoover, S. E., Ampel, N. M., Wheat, L. J., & Knox, K. S. (2017). Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis with the MiraVista IgG and IgM Detection Enzyme Immunoassay. Journal of Clinical Microbiology, 55(3), 893-901. https://doi.org/10.1128/JCM.01880-16
Malo J, et al. Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis With the MiraVista IgG and IgM Detection Enzyme Immunoassay. J Clin Microbiol. 2017;55(3):893-901. PubMed PMID: 28053216.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis with the MiraVista IgG and IgM Detection Enzyme Immunoassay. AU - Malo,Joshua, AU - Holbrook,Eric, AU - Zangeneh,Tirdad, AU - Strawter,Chris, AU - Oren,Eyal, AU - Robey,Ian, AU - Erickson,Heidi, AU - Chahal,Racquel, AU - Durkin,Michelle, AU - Thompson,Cindy, AU - Hoover,Susan E, AU - Ampel,Neil M, AU - Wheat,L Joseph, AU - Knox,Kenneth S, Y1 - 2017/01/04/ PY - 2016/09/09/received PY - 2016/12/16/accepted PY - 2017/1/6/pubmed PY - 2017/7/27/medline PY - 2017/1/6/entrez KW - coccidioidomycosis KW - endemic mycoses KW - fungal infections KW - serology SP - 893 EP - 901 JF - Journal of clinical microbiology JO - J Clin Microbiol VL - 55 IS - 3 N2 - Coccidioidomycosis is a common cause of community-acquired pneumonia in areas of the southwestern United States in which the disease is endemic. Clinical presentations range from self-limited disease to severe disseminated disease. Therefore, early and accurate diagnosis is essential to ensure appropriate treatment and monitoring. Currently available diagnostic tests have variable accuracy, particularly in certain patient populations, and new tests may offer improved accuracy for the diagnosis of coccidioidomycosis. Serum samples from 103 cases of coccidioidomycosis and 373 controls were tested for IgG and IgM antibodies using the MVista anti-Coccidioides antibody enzyme immunoassay. Serum specimens from 170 controls from areas in which the disease is endemic and 44 cases were tested by immunodiffusion at MiraVista Diagnostics. The sensitivity of the MVista antibody assay was 88.3%, and the specificity was 90%. The sensitivity was maintained in the presence of immunocompromising conditions or immunosuppressive therapies. The sensitivity of immunodiffusion was 60.2%, and the specificity was 98.8%. The sensitivity of complement fixation (62 cases) was 66.1%, but the specificity could not be determined. The MVista anti-Coccidioides antibody enzyme immunoassay offers improved sensitivity, compared with immunodiffusion and complement fixation, is not impaired in immunocompromised patients, and permits highly reproducible semiquantification. SN - 1098-660X UR - https://www.unboundmedicine.com/medline/citation/28053216/Enhanced_Antibody_Detection_and_Diagnosis_of_Coccidioidomycosis_with_the_MiraVista_IgG_and_IgM_Detection_Enzyme_Immunoassay_ L2 - http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=28053216 DB - PRIME DP - Unbound Medicine ER -